路凡;何良志;滕飞;耿彬;李睿;张小辉;赵良功;夏亚一;

• 1:兰州大学第二医院骨科甘肃省骨关节疾病重点实验室

摘要(Abstract)：

肺腺癌转移相关转录本1 (metastasis associated lung adenocarcinoma transcript 1, MALAT1)是长链非编码RNA(long noncoding RNA, lncRNA)的一种,其参与骨肉瘤(osteosarcoma, OS)发生发展的机制十分复杂,可通过与miRNA作用等方式促进骨肉瘤细胞的增殖,可通过上调细胞周期蛋白依赖性激酶9(cyclin-dependent kinase 9,CDK9)的水平等途径抑制骨肉瘤细胞的凋亡,也可通过促进转化生长因子A(transforming growth factor A, TGFA)的表达等方式介导骨肉瘤细胞的侵袭转移。总之,MALAT1可通过多种作用机制参与到骨肉瘤细胞的进展过程中,本文拟对MALAT1在骨肉瘤细胞增殖、凋亡和侵袭转移过程中的分子作用机制进行综述。

关键词(KeyWords)： 骨肉瘤;长链非编码RNA;MALAT1;发生发展;研究进展

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金（编号：81874017和81672207）;; “中央高校基本科研业务费专项资金”重点研究基地创新项目（编号：lzujbky-2018-kb16）;; 兰州市科技计划项目（编号：2017-4-88和2018-3-52）;; 兰州大学第二医院“萃英科技创新”计划（编号：CY2017-ZD02和CY2017-QN12）

作者(Author): 路凡;何良志;滕飞;耿彬;李睿;张小辉;赵良功;夏亚一;

Email:

DOI:

参考文献(References)：

• [1] Bielack S, Carrle D, Jost L. Osteosarcoma:ESMO Clinical Recommendations for diagnosis, treatment and follow-up[J]. An Oncol,2008, 19(Supplement 2):ii94-ii96.
• [2] Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004:Data from the Surveillance, Epidemiology, and End Results Program[J]. Cancer, 2009, 115(7):1531-1543.
• [3] Bielack S, Kempfbielack B, Schwenzer D, et al. prognostic factors in high-grade osteosarcoma of the extremities or trunk:an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols[J]. J Clin Oncol, 2002, 20(3):776-790.
• [4] He X, Gao Z, Xu H, et al. A meta-analysis of randomized control trials of surgical methods with osteosarcoma outcomes[J]. J Orthop Surg Res, 2017, 12(1):5.
• [5] Guttman M, Rinn JL. Modular regulatory principles of large noncoding RNAs[J]. Nature, 2012, 482(7385):339-346.
• [6] Tripathi V, Ellis JD, Shen Z, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation[J]. Molecular Cell, 2010, 39(6):925-938.
• [7] Fellenberg J, Bernd L, Delling G, et al. Prognostic significance of drug-regulated genes in high-grade osteosarcoma[J]. Modern Pathology, 2007, 20(10):1085-1094.
• [8] Gao KT, Lian D. Long non-coding RNA MALAT1 is an independent prognostic factor of osteosarcoma[J]. Eur Rev Med Pharmacol Sci, 2016, 20(17):3561-3565.
• [9] Kodach LL, Bleuming SA, Musler AR, et al. The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer[J]. Cancer, 2010, 112(2):300-306.
• [10] Li Q, Pan X, Wang X, et al. Long noncoding RNA MALAT1 promotes cell proliferation through suppressing miR-205 and promoting SMAD4 expression in osteosarcoma[J]. Oncotarget, 2017, 8(63):106648-106660.
• [11] Chen Y, Huang W, Sun W, et al. LncRNA MALAT1 Promotes Cancer Metastasis in Osteosarcoma via Activation of the PI3K-Akt Signaling Pathway[J]. Cell Physiol Biochem, 2018, 51:1313-1326.
• [12] Liu K, Huang J, Ni J, et al. MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p[J]. Cell Cycle, 2017, 16(6):578-587.
• [13] Cai CK, Zhao GY, Tian LY, et al. miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma[J]. Oncology Reports, 2012, 28(5):1764-1770.
• [14] Duan G, Zhang C, Xu C, et al. Knockdown of MALAT1 inhibits osteosarcoma progression via regulating the miR-34a/cyclin D1 axis.[J]. Int J Oncol, 2019, 54(1):17-28.
• [15] Dong Y, Liang G, Yuan B, et al. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway[J]. Tumor Biology, 2015, 36(3):1477-1486.
• [16] Zhi-Chang Z, Chun T, Yang D, et al. Targeting the long noncoding RNA MALAT1 blocks the pro-angiogenic effects of osteosarcoma and suppresses tumour growth[J]. Int J Biol Sci, 2017, 13(11):1398-1408.
• [17] Li S, Wang Q, Qiang Q, et al. Sp1-mediated transcriptional regulation of MALAT1 plays a critical role in tumor[J]. J Cancer Res Clin Oncol, 2015, 141(11):1909-1920.
• [18] Hu Q, Li S, Chen C, et al. 17β-Estradiol treatment drives Sp1 to upregulate MALAT-1 expression and epigenetically affects physiological processes in U2OS cells[J]. Molecular Med Rep, 2017, 15(3):1335.
• [19] Wang S, Fischer PM. Cyclin-dependent kinase 9:a key transcriptional regulator and potential drug target in oncology, virology and cardiology[J]. Trends Pharmacol Sci, 2008, 29(6):0-313.
• [20] Ren D, Zheng H, Fei S, et al. MALAT1 induces osteosarcoma progression by targeting miR-206/CDK9 axis[J]. J Cell Physiol, 234(1):950-957.
• [21] Wang X, Nagase H, Watanabe T, et al. Inhibition of MMP-9 transcription and suppression of tumor metastasis by pyrrole-imidazole polyamide[J]. Cancer Sci, 2010, 101(3):759-766.
• [22] Taniguchi M, Fujiwara K, Nakai Y, et al. Inhibition of malignant phenotypes of human osteosarcoma cells by a gene silencer, a pyrrole–imidazole polyamide, which targets an E-box motif[J].FEBS Open Bio, 2014, 4:328-334.
• [23] Ottaviani G, Jaffe N. The Epidemiology of osteosarcoma[J]. Cancer Treatment Res, 2009, 152:3.
• [24] Yuxiu S, Baoli Q. Long noncoding RNA MALAT1 regulates HDAC4-mediated proliferation and apoptosis via decoying of miR-140-5p in osteosarcoma cells[J]. Cancer Medicine, 2018, 1:1-10.
• [25] O"Connor K, Chen M. Dynamic functions of RhoA in tumor cell migration and invasion[J]. Small GTPases, 2013, 4(3):141-147.
• [26] Cai X, Liu Y, Yang W, et al. Long noncoding RNA MALAT1 as a potential therapeutic target in osteosarcoma[J]. J Orthop Res,2016, 34(6):932-941.
• [27] Wang Y, Zhang Y, Yang T, et al. Long non-coding RNA MALAT1for promoting metastasis and proliferation by acting as a ceRNA of miR-144-3p in osteosarcoma cells[J]. Oncotarget, 2017, 8(35):59417.
• [28] Sun R, Shen J, Gao Y, et al. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential[J]. Oncotarget, 2016, 7(25):38333-38346.
• [29] Huo Y, Li Q, Wang X, et al. MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2[J]. Oncotarget, 2017, 8(29):46993-47006.
• [30] Zhi-Chang Z, Chun T, Yang D, et al. Targeting LncRNAMALAT1 suppresses the progression of osteosarcoma by altering the expression and localization ofβ-catenin[J]. J Cancer, 2018, 9(1):71-80.
• [31] Luo W, He H, Xiao W, et al. MALAT1 promotes osteosarcoma development by targeting TGFA via MIR376A[J]. Oncotarget, 2016,7(34):54733-54743.
• [32] Kim CG, Lee H, Gupta N, et al. Role of forkhead box class O proteins in cancer progression and metastasis[J]. Seminars in Cancer Biol, 2017:S1044579X17300925.
• [33] Wang J, Sun G. FOXO1-MALAT1-miR-26a-5p feedback loop mediates proliferation and migration in osteosarcoma cells[J]. Oncol Res, 2017, 25(9):1021-1029.